JP2007535520A - 抗腫瘍作用を有するインドール及びアザインドール誘導体 - Google Patents

抗腫瘍作用を有するインドール及びアザインドール誘導体 Download PDF

Info

Publication number
JP2007535520A
JP2007535520A JP2007510035A JP2007510035A JP2007535520A JP 2007535520 A JP2007535520 A JP 2007535520A JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007535520 A JP2007535520 A JP 2007535520A
Authority
JP
Japan
Prior art keywords
dimethoxy
indole
methoxyphenyl
group
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007510035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535520A5 (enExample
Inventor
ファリナ・カルロ
ガガリアルディ・ステファニア
ミシアノ・パオラ
セレスティニ・パオロ
ズニノ・フランコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NiKem Research SRL
Original Assignee
NiKem Research SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NiKem Research SRL filed Critical NiKem Research SRL
Publication of JP2007535520A publication Critical patent/JP2007535520A/ja
Publication of JP2007535520A5 publication Critical patent/JP2007535520A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2007510035A 2004-04-30 2005-04-27 抗腫瘍作用を有するインドール及びアザインドール誘導体 Pending JP2007535520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000874A ITMI20040874A1 (it) 2004-04-30 2004-04-30 Derivati indolici ed azaindolici con azione antitumorale
PCT/EP2005/051908 WO2005105213A2 (en) 2004-04-30 2005-04-27 Indole and azaindole derivatives with antitumor action

Publications (2)

Publication Number Publication Date
JP2007535520A true JP2007535520A (ja) 2007-12-06
JP2007535520A5 JP2007535520A5 (enExample) 2008-06-19

Family

ID=34968098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510035A Pending JP2007535520A (ja) 2004-04-30 2005-04-27 抗腫瘍作用を有するインドール及びアザインドール誘導体

Country Status (7)

Country Link
US (1) US20070248672A1 (enExample)
EP (1) EP1750687A2 (enExample)
JP (1) JP2007535520A (enExample)
AU (1) AU2005237788A1 (enExample)
CA (1) CA2564249A1 (enExample)
IT (1) ITMI20040874A1 (enExample)
WO (1) WO2005105213A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150058441A (ko) * 2012-09-21 2015-05-28 비보룩스 아베 고형 종양의 치료 수단 및 방법
JP2016516828A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2018521986A (ja) * 2015-06-17 2018-08-09 ファイザー・インク 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
CA2951295C (en) * 2007-04-16 2020-04-28 Abbvie Inc. 7-nonsubstituted indole mcl-1 inhibitors
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP5687704B2 (ja) * 2009-10-07 2015-03-18 カロ バイオ アクチェブラーグ 新規エストロゲン受容体リガンド
HRP20161092T1 (hr) 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
AU2013232066B2 (en) 2012-03-16 2017-07-06 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
LT2825542T (lt) 2012-03-16 2016-12-27 Vitae Pharmaceuticals, Inc. Kepenų x receptoriaus moduliatoriai
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US11866409B2 (en) 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
UY39579A (es) 2020-12-22 2022-07-29 Novartis Ag COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1286701A (en) * 1969-02-12 1972-08-23 Sumitomo Chemical Co Pyridophenone derivatives and conversion to benzodiazepine derivatives
JPS4969698A (enExample) * 1972-09-25 1974-07-05
JPS5566578A (en) * 1978-10-02 1980-05-20 Schering Corp Novel 22substitutedd33heterocyclic indoles* their manufacture and medical composition containing them
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
EP0643059A1 (en) * 1993-09-15 1995-03-15 Pfizer Limited 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2003039539A2 (de) * 2001-11-09 2003-05-15 Merck Patent Gmbh Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
US20030105140A1 (en) * 2000-12-07 2003-06-05 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105140A (en) * 1870-07-05 Improvement in cigar-wrapping machines
CA1012147A (en) * 1972-09-25 1977-06-14 Hoffmann-La Roche Limited Indolo quinoline derivatives
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1286701A (en) * 1969-02-12 1972-08-23 Sumitomo Chemical Co Pyridophenone derivatives and conversion to benzodiazepine derivatives
JPS4969698A (enExample) * 1972-09-25 1974-07-05
JPS5566578A (en) * 1978-10-02 1980-05-20 Schering Corp Novel 22substitutedd33heterocyclic indoles* their manufacture and medical composition containing them
JPH04211651A (ja) * 1990-03-26 1992-08-03 Takeda Chem Ind Ltd 骨吸収抑制剤およびインドール誘導体
EP0643059A1 (en) * 1993-09-15 1995-03-15 Pfizer Limited 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
US20030105140A1 (en) * 2000-12-07 2003-06-05 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2003039539A2 (de) * 2001-11-09 2003-05-15 Merck Patent Gmbh Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150058441A (ko) * 2012-09-21 2015-05-28 비보룩스 아베 고형 종양의 치료 수단 및 방법
KR102190768B1 (ko) 2012-09-21 2020-12-14 비보룩스 아베 고형 종양의 치료 수단 및 방법
JP2016516828A (ja) * 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
JP2018521986A (ja) * 2015-06-17 2018-08-09 ファイザー・インク 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
WO2005105213A3 (en) 2006-06-22
WO2005105213A2 (en) 2005-11-10
ITMI20040874A1 (it) 2004-07-30
EP1750687A2 (en) 2007-02-14
CA2564249A1 (en) 2005-11-10
AU2005237788A1 (en) 2005-11-10
US20070248672A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
JP2007535520A (ja) 抗腫瘍作用を有するインドール及びアザインドール誘導体
CN112867721B (zh) Sting激动性化合物
US10851092B2 (en) Pyridine compound
TWI567059B (zh) 吡咯啶－２，５－二酮衍生物、醫藥組合物及用做為ｉｄｏ１抑制劑之方法
JP6912486B2 (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CN105683166A (zh) 取代的嘧啶Bmi-1抑制剂
JP2021107456A (ja) インドリノン化合物の使用
CA3107548A1 (en) Smad3 inhibitors
AU2010333083B2 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2655359B1 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2010096395A1 (en) Amides as kinase inhibitors
CN104662022A (zh) 治疗实体瘤的手段和方法
EP3397632A1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2016153394A1 (ru) Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
HK40052813A (en) Pyridine salts and process
HK40045137B (zh) Smad3抑制剂
HK40053745A (en) Sting-agonist compound
HK40053745B (zh) Sting激动性化合物
HK40005148A (en) Pyridine compound
HK40005148B (en) Pyridine compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124